Document is current
Any future updates will be listed below
-
Authors
Ashry, Ramy https://orcid.org/0000-0001-6474-113X
Krämer, Oliver H. https://orcid.org/0000-0003-3973-045X
- License Information
-
More Information
Article History
Received: 6 July 2025
Accepted: 2 September 2025
First Online: 8 September 2025
Declarations
:
: O.H.K. declares the patents “The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity, WO/2004/027418”, “Novel HDAC6 inhibitors and their uses, WO2016020369A1”, and “Synthesis, pharmacology and use of new and selective FMS-like tyrosine kinase 3 (FLT3) inhibitors, WO2019/034538”, and advisory consultant activity for BASF, Ludwigshafen, Germany. There is no direct financial relationship with the organizations that sponsor our research, and the BASF had no influence on this work. Thus, there are no direct competing interests. R.A. declares no conflict of interest.
